scPharmaceuticals
Subcutaneous drug-device combination therapeutics (FUROSCIX) -- acquired by MannKind Corporation, Oct 2025
Privately held: no public share price · United States
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | NKCC2Small molecule | Heart FailureChronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $16M | $4.1M | $41M | $18M | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q1 | $12M | $4.6M | $58M | $20M | report ↗ |
| 2024-Q3 | $10M | $3.5M | $91M | $35M | report ↗ |
| 2024-Q2 | $8.1M | $2.7M | $39M | $17M | report ↗ |
| 2024-Q1 | $6.1M | $2.7M | $58M | $14M | report ↗ |
| 2023-Q3 | $3.8M | $3.4M | $35M | $16M | report ↗ |
| 2023-Q2 | $1.6M | $2.9M | $71M | $14M | report ↗ |
| 2023-Q1 | $2.1M | $2.1M | $75M | $11M | report ↗ |
| 2022-Q3 | — | $3.7M | $41M | $10M | report ↗ |
| 2022-Q2 | — | $5.1M | $41M | $9.7M | report ↗ |
| 2022-Q1 | — | $4.3M | $52M | $7.7M | report ↗ |
| 2021-Q3 | — | $3.7M | $80M | $6.5M | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $36M | $12M | $76M | $85M | report ↗ |
scPharmaceuticals reported revenue of $36.33M, up 167.3% YoY, R&D spend of $12.1M, up 2.5% YoY, cash and equivalents of $75.66M, and a quarterly net burn of $85.15M for fiscal year 2024.
Figures only: this period's report disclosed no narrative text